Open Access<p>BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study</p>
Author(s) -
Xingbing Huang,
Hui Xiong,
Hongbo He,
Fang Mei,
Bin Sun,
Sumiao Zhou,
Su Yan,
Wei Zheng,
Yuping Ning
Publication year - 2020
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s248190
Subject(s) - electroconvulsive therapy , medicine , ketamine , propofol , antidepressant , brief psychiatric rating scale , brain derived neurotrophic factor , treatment resistant depression , anesthesia , depression (economics) , neurotrophic factors , pharmacology , psychiatry , hippocampus , electroconvulsive shock , psychosis , receptor , macroeconomics , economics
Ketamine and propofol have become increasingly popular in electroconvulsive therapy (ECT) anaesthesia. This study was conducted to examine whether changes in serum levels of brain-derived neurotrophic factor (BDNF) are associated with the antidepressant effects of ketofol, a combination of ketamine and propofol, in ECT for patients with treatment-resistant depression (TRD).